FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2552034981> ?p ?o ?g. }

• W2552034981 abstract "Abstract 133 Background: PMBCL represents a unique lymphoma type in the WHO classification and shares overlapping histological and gene expression features with both diffuse large B-cell (DLBCL) and classical Hodgkin lymphoma. Similar to DLBCL, PMBCL may show loss of expression of the major histocompatibility class II (MHC II) antigens, which correlates with inferior patient survival (Rimsza, Blood 2006). MHC II proteins are expressed on antigen-presenting cells and are important in eliciting immune responses. In DLBCL, decreased expression of HLA-DR is related to loss of immunosurveillence. Our aim was to validate HLA-DR as an important prognostic biomarker in PMBCL and correlate it with immune response in a cohort of patients treated with multi-agent chemotherapy. Methods: A tissue microarray block was built with duplicate 0.6mm cores of paraffin embedded diagnostic biopsies from 103 patients treated with CHOP/CHOP-like chemotherapy at the BC Cancer Agency (1980-2005). Standard immunohistochemistry was performed with CD20, HLA-DR (IgG2b), CD3, CD4, CD8, CD57, CD68 and cytotoxic markers (TIA1 & Granzyme B). HLA-DR expression was evaluated using a histoscore (intensity of staining and % of positive malignant cells) and correlated with the content (%) of different non-neoplastic infiltrating T-cell subsets and macrophages. Univariate & multivariate analyses were used to characterize overall survival (OS) and progression free survival (PFS). Results: The median follow-up of living patients was 10 years. The IPI predicted OS (p=0.042) but not PFS. Of the 92 cases with interpretable staining, 32 were positive for HLA-DR and 60 negative, with 10-year OS of 86% vs. 61% (p=0.006) and 2-year PFS of 78% vs. 53% (p=0.018), respectively. A Cox multivariate model established both HLA-DR status and IPI as independent predictors of OS (RR=0.3, 95%CI=0.12–0.75, p=0.01; RR=2.9, 95%CI=1.2–6.9, p=0.06, respectively). HLA-DR expression correlated significantly with increased content of all analyzed T cell markers, especially CD3, CD8 and TIA1 (x2, p<0.001), but not with macrophage content (CD68). Of all non-malignant markers, only TIA1+ cell content significantly correlated with survival. Of the 83 cases with interpretable staining, 43 had more than 10% of infiltrating TIA1+ cells and 40 had less, with 10-year OS of 83% vs. 57% (p=0.0014) and 2-year PFS of 76% vs. 50% (p=0.014), respectively. In multivariate analysis, including IPI and HLA-DR and cytotoxic markers, only TIA1 status was an independent predictor of OS (RR=0.3, 95%CI=0.11–0.63, p=0.003). Conclusions: We validated the negative prognostic importance of loss of HLA-DR expression by neoplastic B cells in PMBCL patients treated with multi-agent chemotherapy in a single institution experience. Loss of HLA-DR expression correlated with decreased numbers of infiltrating benign T cell populations, especially CD8+ and TIA1+ cells, where decreased cytotoxic T cell content correlated independently with inferior survival. This study shows loss of immunogenicity and immunosurveillance are key mechanisms in the response to treatment of PMBCL patients and suggests that specific therapies focused on this pathway may benefit patients. Disclosures: Connors: Roche Canada (F Hoffmann-La Roche): Research Funding. Gascoyne:Roche Canada, Genentech, Lilly, Millennium : Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding." @default.
• W2552034981 created "2016-11-30" @default.
• W2552034981 creator A5008961404 @default.
• W2552034981 creator A5014743270 @default.
• W2552034981 creator A5017873196 @default.
• W2552034981 creator A5022658681 @default.
• W2552034981 creator A5031758990 @default.
• W2552034981 creator A5048030695 @default.
• W2552034981 date "2009-11-20" @default.
• W2552034981 modified "2023-10-01" @default.
• W2552034981 title "HLA-DR Protein Expression Correlates with Non-Neoplastic T-Cell Infiltration and Predicts Survival in Patients with Primary Mediastinal Large B Cell Lymphoma (PMBCL) Treated with CHOP Chemotherapy." @default.
• W2552034981 doi "https://doi.org/10.1182/blood.v114.22.133.133" @default.
• W2552034981 hasPublicationYear "2009" @default.
• W2552034981 type Work @default.
• W2552034981 sameAs 2552034981 @default.
• W2552034981 citedByCount "2" @default.
• W2552034981 countsByYear W25520349812012 @default.
• W2552034981 countsByYear W25520349812014 @default.
• W2552034981 crossrefType "journal-article" @default.
• W2552034981 hasAuthorship W2552034981A5008961404 @default.
• W2552034981 hasAuthorship W2552034981A5014743270 @default.
• W2552034981 hasAuthorship W2552034981A5017873196 @default.
• W2552034981 hasAuthorship W2552034981A5022658681 @default.
• W2552034981 hasAuthorship W2552034981A5031758990 @default.
• W2552034981 hasAuthorship W2552034981A5048030695 @default.
• W2552034981 hasConcept C142724271 @default.
• W2552034981 hasConcept C143998085 @default.
• W2552034981 hasConcept C147483822 @default.
• W2552034981 hasConcept C167672396 @default.
• W2552034981 hasConcept C188280979 @default.
• W2552034981 hasConcept C193270364 @default.
• W2552034981 hasConcept C203014093 @default.
• W2552034981 hasConcept C204232928 @default.
• W2552034981 hasConcept C2778476033 @default.
• W2552034981 hasConcept C2778559949 @default.
• W2552034981 hasConcept C2779338263 @default.
• W2552034981 hasConcept C2779725641 @default.
• W2552034981 hasConcept C502942594 @default.
• W2552034981 hasConcept C71924100 @default.
• W2552034981 hasConceptScore W2552034981C142724271 @default.
• W2552034981 hasConceptScore W2552034981C143998085 @default.
• W2552034981 hasConceptScore W2552034981C147483822 @default.
• W2552034981 hasConceptScore W2552034981C167672396 @default.
• W2552034981 hasConceptScore W2552034981C188280979 @default.
• W2552034981 hasConceptScore W2552034981C193270364 @default.
• W2552034981 hasConceptScore W2552034981C203014093 @default.
• W2552034981 hasConceptScore W2552034981C204232928 @default.
• W2552034981 hasConceptScore W2552034981C2778476033 @default.
• W2552034981 hasConceptScore W2552034981C2778559949 @default.
• W2552034981 hasConceptScore W2552034981C2779338263 @default.
• W2552034981 hasConceptScore W2552034981C2779725641 @default.
• W2552034981 hasConceptScore W2552034981C502942594 @default.
• W2552034981 hasConceptScore W2552034981C71924100 @default.
• W2552034981 hasLocation W25520349811 @default.
• W2552034981 hasOpenAccess W2552034981 @default.
• W2552034981 hasPrimaryLocation W25520349811 @default.
• W2552034981 hasRelatedWork W1986289782 @default.
• W2552034981 hasRelatedWork W2166656557 @default.
• W2552034981 hasRelatedWork W2211630813 @default.
• W2552034981 hasRelatedWork W2336457401 @default.
• W2552034981 hasRelatedWork W2401241572 @default.
• W2552034981 hasRelatedWork W2421552586 @default.
• W2552034981 hasRelatedWork W2468444841 @default.
• W2552034981 hasRelatedWork W2473984749 @default.
• W2552034981 hasRelatedWork W2531118285 @default.
• W2552034981 hasRelatedWork W2551458203 @default.
• W2552034981 hasRelatedWork W2559911134 @default.
• W2552034981 hasRelatedWork W2570893191 @default.
• W2552034981 hasRelatedWork W2587561344 @default.
• W2552034981 hasRelatedWork W2593953634 @default.
• W2552034981 hasRelatedWork W2610996293 @default.
• W2552034981 hasRelatedWork W2909238997 @default.
• W2552034981 hasRelatedWork W2921139725 @default.
• W2552034981 hasRelatedWork W2981017397 @default.
• W2552034981 hasRelatedWork W3036115709 @default.
• W2552034981 hasRelatedWork W2977897352 @default.
• W2552034981 isParatext "false" @default.
• W2552034981 isRetracted "false" @default.
• W2552034981 magId "2552034981" @default.
• W2552034981 workType "article" @default.